CULTURE

We are cancer-fighting pioneers,
guided by an epic purpose.

At Epic Sciences, we constantly strive to push the boundaries of medical technology, finding vital answers to personalize and transform human health.

More than just science.
Living life to the fullest.

Our people – talented, dedicated, and passionate about their vision – make the difference. We are a culture of collaboration. Working (and playing) as a team empowers us to bring an irrepressible energy to everything we do. It’s challenging, but never dull.

WATCH OUR EPIC STORY VIDEO

CORE VALUES

These values are our North Star, guiding us in the quest to revolutionize cancer care.

Principled

Be accountable, ethical, data-driven and transparent.

PATIENT-FOCUSED

Relentlessly strive to improve the duration and quality of patient lives.

COMMITTED TO EXCELLENCE

Maintain the highest quality of data, products, services and customer experience.

INNOVATIVE

Constantly pursue the next level of discovery in all our activities.

COLLABORATIVE

Work in concert with one another and with our customers.

COURAGEOUS

Confront all challenges with moral and intellectual integrity.

DIVERSITY & INCLUSION

 

Our commitment to our people and our community

 

We champion diversity and inclusivity at Epic and in our community. We believe people do their best work in an environment that recognizes and appreciates different perspectives, backgrounds, and cultures.

We celebrate the differences our people bring to the workplace: race, gender, age, religion, and identity – and believe that those differences make us better.

Within our community, we promise to nurture and develop talent, to celebrate, support and sustain diversity, and help develop the next generation of scientists in our discipline.

 

Epic Sciences’ Diversity and Inclusion Action Team

To support and focus the company’s energy around diversity and inclusion, we’re proud to identify the first D&I Action Team members: Priscilla Ontiveros, Sr. Alliance Manager, Jayne Bersabe, Senior Project Coordinator, Sheila DeVera, Project Coordinator, and Mark Frilles, Research Associate. These people have volunteered to help shape the outcomes we will generate for our first year, and we want to recognize and thank them for their commitment. If you are interested in what the D&I Action Team is doing or are interested in volunteering as well, please see Jim Kreiss in Human Resources.




The San Marcos Promise Partnership

200x91

Epic Sciences is proud to be partnering with The San Marcos Promise, a nonprofit foundation working to connect education, business, and community leaders to impact student futures.  SMP’s programs target students in the San Marcos Unified School District (SMUSD), where 69% of the 21,000 K-12 students are students of color, and 41.7% of students qualify for the free or reduced meal program.

SMP’s goal is to help SMUSD students discover their interests and strengths and take the necessary steps to prepare for a successful career. With a STEM-focus, SMP’s programs have the potential to increase college enrollment rates among all students and increase entry-level wages for students directly joining the workforce.  Epic Sciences’ volunteers will partner with SMP to provide mentoring, career advice, and coaching to students.

 

 


OUR MISSION

Extend patient lives by delivering the clarity to guide treatment decisions.

OUR VISION

Unlocking the power of comprehensive cancer profiling to empower real-time, precision medicine.

CAREERS

We’re looking for inspired visionaries – diverse individuals with a passion for precision and a deep commitment to making a profound difference. Join us to transform cancer care and extend lives, cell by cell, person by person.

LEADERSHIP

Lloyd Sanders

President and Chief Executive Officer

Lloyd Sanders joined Epic Sciences as President and Chief Executive Officer in 2019 with more than 20 years of diagnostics and pharmaceutical industry experience, most of it focused on oncology. Prior to joining Epic, he served as president of the oncology segment of Myriad Genetics, overseeing the oncology, urology and dermatology commercial organizations. While at Myriad, he was responsible for the sales, marketing, medical, customer service and laboratory operations for numerous market-leading commercial products, including molecular diagnostics for risk assessment, diagnosis/screening, prognosis and selection of therapies for breast, prostate, colorectal and other cancers.

Previously, Mr. Sanders served as chief operating officer at Dey Pharma, a division of Mylan, overseeing sales, marketing and medical affairs, including the EpiPen® flagship brand. Prior to Dey Pharma, he held several leadership positions including responsibility for the commercial growth of a number of oncology products at Sanofi-Synthelabo, subsequently Sanofi-Aventis, where he led the successful restructuring and integration of two companies’ sales forces after the merger. Mr. Sanders started his pharmaceutical career and participated in oncology product launches at Pharmacia (now Pfizer).

Mr. Sanders earned a Bachelor’s business degree with an emphasis in marketing from Memphis State University.

Peter Kuhn

Founder & Chief Scientific Advisor

Peter Kuhn, PhD, is Founder and Chief Scientific Advisor at Epic Sciences. He is the principal architect of the Epic Sciences platform and has invested his career into the research, development, and the clinical utility of the liquid biopsy. His vision of translating innovation in research to meaningful products for patient care is driving his everyday efforts.

Dr. Kuhn is the Dean’s Professor of Biological Sciences, Professor of Medicine, Aerospace & Mechanical Engineering, and Biomedical Engineering at the University of Southern California. He also serves as the Director of the USC Michelson Convergent Science Institute in Cancer (CSI-Cancer) and the deputy director of the Convergent Science – Virtual Cancer Center. He holds a chair as Honorary Professor of Cancer Science at the University of Manchester in the United Kingdom.

Previously, Dr. Kuhn held faculty appointments at The Scripps Research Institute and at Stanford University. While at Stanford, Dr. Kuhn established the structural genomics research enterprise and focused his research on technology developments in structural biology that were utilized by breakthrough research such as Dr. Roger Kornberg’s (Nobel prize 2006) structure determination of the RNA Polymerase. Dr. Kuhn joined Scripps and advanced technologies that led to the structure determination of the human b2AR GPCR with collaborators including Dr. Brian Kobilka (Nobel prize 2012).

Dr. Kuhn is a physicist who trained initially at the Julius Maximilians Universität Würzburg, Germany, before receiving his Masters in Physics at the University of Albany, Albany, NY in 1993 including research with Drs. Michael Radermacher and Joachim Frank (Nobel prize 2017) in electron microscopy and his Ph.D. in 1995 with Dr. Patrick VanRoey in X-ray crystallography. He then moved to Stanford University where he joined the faculties of Medicine and Accelerator Physics as tenure track Assistant Professor. From 2002 to 2014 he established the Physics Oncology program at The Scripps Research in La Jolla, CA as tenured Associate Professor before joining USC in 2014. His research and inventions have resulted in over 300 peer-reviewed publications, which have been cited over twenty-thousand times.

Joel Smith

Chief Financial Officer & General Counsel

Joel Smith serves as Chief Financial Officer and General Counsel at Epic Sciences.

A veteran legal professional with more than 20 years of experience in the life sciences and biopharmaceutical industries, Mr. Smith brings a breadth of knowledge in strategic corporate development, complex commercial transactions, licensing, securities law, corporate governance and regulatory compliance. Smith has served as a senior executive and general counsel for a number of biotechnology and life sciences companies, including BioQ, Triad Therapeutics, and Sientra, Inc. At Sientra, Smith was responsible for all of its legal affairs including corporate compliance, commercialization policies, and intellectual property. He was a primary contributor to its premarket application for FDA approval of its implants and in the preparation of the prospectus used in its initial public offering on Nasdaq.

Most recently, Smith was the managing counsel of Qualcomm Life, the medical device subsidiary of Qualcomm where he and his team supported global sales and business development teams.

Smith earned his Juris Doctorate, cum laude, and a Master of Business Administration, with highest distinction, from the University of Michigan, as well as a Bachelor of Science in Cellular and Molecular Biology and Economics. He is a member of the State Bar of California.

Richard Wenstrup, MD

Chief Medical Officer

Richard J. Wenstrup, MD joins Epic Sciences as Chief Medical Officer, bringing more than 25 years of clinical leadership experience managing life science companies before joining industry from academia.

Dr. Wenstrup was previously chief medical officer for Oxford Immunotec, Inc., where he oversaw research and development, product development, regulatory, medical and clinical affairs. From 2006-2017, he served as chief medical officer for Myriad Genetics, where he built and led the clinical and medical affairs team to support a multi-fold increase in revenue during his tenure. Dr. Wenstrup was actively involved in the company’s product development, M&A and in-licensing activities.‍

Prior to joining industry, Dr. Wenstrup served as a tenured professor of pediatrics in human genetics at Cincinnati Children’s Hospital Medical Center and as a tenured professor of biomedical engineering at the University of Cincinnati, where he earned his medical degree. He was internationally recognized as a leader in inherited disorders of the musculoskeletal system and was principal investigator on multiple research grants from the National Institutes of Health and the FDA Orphan Products Grant Program. As an entrepreneur, Dr. Wenstrup was the founding director of the Molecular Diagnostics Laboratory at Cincinnati Children’s Hospital and co-founder of Assurex Health, Inc., now a subsidiary of Myriad Genetics, Inc.

Alisa Tubbs

VP, Product Strategy

As Vice President, Product Strategy, Ms. Tubbs has over 20 years of broad industry experience successfully developing technology solutions as well as bringing global products to market. Her expertise driving strategy in the diagnostic space spans from concept creation to address unmet medical needs through clinical evidence build and market access. She has established collaboration and program management teams and processes within top Pharmaceutical companies such as Roche and AstraZeneca and is committed to improving cancer patient care through innovation.

Jim Walther

VP, Business Development and Strategic Partnerships

A proven leader with a history of bringing clinical diagnostics to market, Mr. Walther comes to Epic Sciences after serving as the Global Head of Genomics Business Development at Q2 Solutions and the Vice President of Business Development and Strategic Partnerships at HTG Molecular. His expertise ranges from advancing molecular technologies and diagnostics by collaborating with large global pharmaceutical and molecular diagnostic companies to clinical labs and biotech settings.  His experience spans all phases of drug development as well as bringing to market a number of globally approved solutions to fulfill pharmaceutical development and patient care.

Mr. Walther earned an MBA from University of Colorado at Boulder and Biomedical and Political Science degrees from Colorado State University.

Eva Wang

VP, Translational Research and Development

Eva Wang, Ph.D. joins Epic Sciences with more than 15 years of industrial and academic experience focused on the intersection of computer science, biology, machine learning, and statistics spanning biomedical research, molecular diagnostics, and therapeutics. Before Epic Sciences, Dr. Wang held various leadership positions with responsibilities spanning from dry lab to R&D and Operations at four successful biotech startup companies, one of which was acquired and three completed IPOs. She recently served at the Gladstone Institutes, where she led a team of cross-disciplinary scientists and engineers to bring cutting edge technology to the Gladstone scientific community. Dr. Wang holds a BS in Microbiology, Ph.D. in computer science from UC Santa Cruz, and an MBA from the Wharton School.

BOARD OF DIRECTORS

greg lucier

Chairman

Greg Lucier is a 25-year veteran of the healthcare industry. He currently heads Corza Health, Inc., a mergers and acquisition healthcare company focused on life science and medical technology.

Mr. Lucier most recently served as Chairman and CEO of NuVasive, an innovative medical device company specializing in minimally-invasive spine surgery that grew revenue from approximately $775 million to more than $1 billion in just over three years as CEO. In addition to continuing to serve as the Chairman of NuVasive, Mr. Lucier serves on the Board of Catalent, Inc., and is a former director of CareFusion Corporation, which was acquired by Becton, Dickinson & Co. in 2015 for approximately $12 billion.

From 2003-2014, he was Chairman and CEO of Life Technologies, a global life sciences company acquired by Thermo Fisher Scientific for $15.4 billion. During his 11-year tenure, he led the company from a small start-up known as Invitrogen in 2003 and directed the acquisition and merger of Invitrogen with Applied Biosystems in 2008 into the renamed Life Technologies. By 2008, he had transformed the organization into a global, world-leading biotechnology firm with 50,000 products, 10,000 employees and nearly $4 billion in sales in more than 180 countries.

Mr. Lucier was responsible for fostering a culture of excellence at Life Technologies, and applied his many years of strategic management experience to help champion an era of personalized medicine. His early career included roles as a Corporate Officer of General Electric and as an executive at GE Medical Systems.

Gregory C. Critchfield, MD

Sera Prognostics

Dr. Critchfield is chairman, president and CEO of Sera Prognostics, Inc. and the former president of Myriad Genetic Laboratories, Inc. He led its transformation into one of the world’s leading molecular diagnostics companies. Under his direction, Myriad Genetic Laboratories launched seven novel molecular diagnostic products across a variety of technology platforms, posting 52 percent compounded annual revenue growth from 1998 through 2010. Prior to joining Myriad, Dr. Critchfield was Chief Medical & Science Officer at Quest Diagnostics, Inc., overseeing medical affairs and innovation activities during its transition from Corning Clinical Laboratories.

He has also served on the faculty of three medical schools — University of Minnesota, Wayne State University, and Duke University — and was a practicing clinical pathologist with Intermountain Healthcare.

Andrew ElBardissi, MD

Deerfield Management

Dr. Andrew ElBardissi is an investor on the Private Transaction team at Deerfield Management. Prior to joining Deerfield, Dr. ElBardissi held roles as an early stage life-sciences investor and as an Investment Banker at J.P. Morgan’s Healthcare practice. Dr. ElBardissi holds an MD from the Mayo Clinic, an MPH in Quantitative Methods from Harvard University, an MBA from Harvard Business School. He received residency training in General Surgery at Harvard Medical School’s Brigham and Women’s Hospital and in Cardiothoracic Surgery at Stanford University. Dr. ElBardissi has been independently funded by the National Institutes of Health (NIH) and the Agency for Healthcare Research and Quality (AHRQ), has over 30 publications in leading peer-reviewed scientific journals, and has presented his research at numerous medical and surgical conferences.

Dr. ElBardissi’s board memberships include Acutus, Farapulse, SentreHeart, Sollis Therapeutics, vWave, Conventus, Neochord, and Incarda Therapeutics.

John Zhao, CFA

Hermed Capital

Mr. John Zhao has 20 years of experience in financial, portfolio management, and risk control with extensive resources in the financial industry.

Mr. Zhao Joined Hermed Capital in 2015, Mr. Zhao led the financial and risk control team, in charge of financial and legal due diligence of all deals, involved in the negotiation, execution, portfolio management, and exit. Prior to joining Hermed Capital, Mr. Zhao has been working in MNCs for years, e.g. the investment director of SK (China), senior manager of PPF (China) Investment and credit rating analyst in DaGong Global Credit Rating Co., Ltd.

Mr. Zhao completed an MBA degree in finance from Shanghai University of Finance and Economics; CFA Charter holder in 2006.

Kim Kamdar, PhD

Domain Associates

Kim Kamdar joined Domain Associates in 2005 and became a partner in 2011. With a background in small molecule drug discovery, Dr. Kamdar has been involved in cutting-edge therapeutic start-ups, using her expertise to identify companies with promising molecular and companion diagnostics that support personalized medicine.

Her present board memberships include Ariosa Diagnostics, Epic Sciences, Lithera, Obalon Therapeutics, ROX Medical, Sera Prognostics, Sonexa Therapeutics, Syndax Pharmaceuticals and Tragara Pharmaceuticals. She was also involved with Corthera until its sale to Novartis in February 2010 and BiPar Sciences until its acquisition by Sanofi-Aventis in April 2009.

Prior to Domain, Dr. Kamdar was a Kauffman Fellow with MPM Capital and a research director at Novartis, where she built and led a research team that focused on the biology, genetics and genomics of model organisms to uncover small molecules that modulated signaling pathway networks. Dr. Kamdar is a founder of Aryzun Pharmaceuticals, a biotech company utilizing protein interaction mapping for small molecule discovery with an initial focus on anti-infectives and oncology.

Dr. Kamdar has authored ten papers and received seven patents. She completed her BA at Northwestern University and her PhD in biochemistry and genetics at Emory University. Dr. Kamdar serves as an advisory board member of Eric Topol’s NIH-supported Clinical and Translational Science Award for Scripps Medicine and the Evolvence India Life Sciences Fund, a private equity fund providing growth capital to Indian pharmaceutical and biotechnology companies. She is also a board member of San Diego’s CONNECT Foundation and the Hastings Center.

Charles Kennedy, MD

Blue Ox Healthcare Partners

Dr. Charles Kennedy has a proven track record as a visionary healthcare leader and has been recognized as an expert in health information technology. Currently, Dr. Kennedy is managing partner at Blue Ox Healthcare Partners, leading their efforts to identify companies with innovations in healthcare services, technology, and devices which can enable providers and health plans to optimize value-based health care strategies.

Prior to joining Blue Ox, Dr. Kennedy held multiple executive positions with Aetna, including Vice President and Chief Medical Officer for Clinical Integration and Chief Population Officer, where he led and implemented population health management programs. Additionally, Dr. Kennedy has served in several executive leadership positions with WellPoint Inc., CareAssured.com, and Blue Shield of California.

Dr. Kennedy’s vast experience and leadership have earned him multiple board appointments and he currently serves as a Ventures Advisory Group Board member with Rethink Health and as an Insurance Industry representative with Health Information Technology Policy Committee.

Dr. Kennedy completed his Bachelor of Science in Genetics at the University of California at Berkeley. He holds an MD in Internal Medicine from the University of California at Los Angeles and his MBA in Corporate Strategy and Health Care Economics from Stanford University.

Murali Prahalad, PhD

Iridia

Murali Prahalad, PhD has two decades of experience in the technology and life science industries. He most recently served as president and CEO of Epic Sciences for 6 years. Under his leadership, Epic commercially launched the first predictive diagnostic test of therapy response in metastatic prostate cancer that has also been reimbursed by Medicare. During the same period Epic significantly expanded partnerships with biopharma companies, its proprietary Functional Cell Profiling technology platform was fully automated for high-volume testing and over $128MM of venture financing was raised to clinically advance a portfolio of practice changing tests in prostate cancer, breast cancer and immuno-oncology. Prior to joining Epic, Dr. Prahalad served as Vice President of Corporate Strategy at Life Technologies, where he helped shape the organic and inorganic investment priorities across the company’s research tools, clinical diagnostic and applied market portfolios. Before Life Technologies, Dr. Prahalad was Vice President of Business Development at Sequenom, Inc.

Dr. Prahalad received a PhD in biochemistry and molecular pharmacology as well as an MS in medical sciences from Harvard University. He also possesses a BS (Hons) in cellular & molecular biology and economics from the University of Michigan.

Lloyd Sanders

Epic Sciences

Lloyd Sanders joined Epic Sciences as President and Chief Executive Officer in 2019 with more than 20 years of diagnostics and pharmaceutical industry experience, most of it focused on oncology. Prior to joining Epic, he served as president of the oncology segment of Myriad Genetics, overseeing the oncology, urology and dermatology commercial organizations. While at Myriad, he was responsible for the sales, marketing, medical, customer service and laboratory operations for numerous market-leading commercial products, including molecular diagnostics for risk assessment, diagnosis/screening, prognosis and selection of therapies for breast, prostate, colorectal and other cancers.

Previously, Mr. Sanders served as chief operating officer at Dey Pharma, a division of Mylan, overseeing sales, marketing and medical affairs, including the EpiPen® flagship brand. Prior to Dey Pharma, he held several leadership positions including responsibility for the commercial growth of a number of oncology products at Sanofi-Synthelabo, subsequently Sanofi-Aventis, where he led the successful restructuring and integration of two companies’ sales forces after the merger. Mr. Sanders started his pharmaceutical career and participated in oncology product launches at Pharmacia (now Pfizer).

Mr. Sanders earned a Bachelor’s business degree with an emphasis in marketing from Memphis State University.